In controlled clinical trials, adverse reactions reported in ≥5% of patients treated with Dibor R and reported more commonly than in patients treated with placebo included nausea, fatigue, dizziness, vomiting and headache. Post-marketing reports with higher doses of bromocriptine used for other indications include psychotic disorders, hallucinations and fibrotic complications.